Toggle menu

ExPRES SEPSIS

Start date:
January 2014
End date:
July 2015
Co-ordinated by:
University of Edinburgh & NHS Lothian

Early Prediction of Severe Sepsis

Aim

To derive a biomarker to allow the identification of patients with confirmed sepsis, and risk stratify patients at risk of developing severe sepsis

Trial Design

A Prospective, multi-centre cohort observational study

Chief Investigator

Professor Tim Walsh, Critical Care Research Group

Local PI

Professor Tim Walsh

Research Team

  • EMERGE Research team
  • Critical Care Research Group
  • Rossi Lab, MRC Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh

Eligibility criteria (summary)

Patients who present to the Emergency Department with suspected sepsis

Further information

http://www.ccm.mvm.ed.ac.uk/

http://www.cir.ed.ac.uk/

Research Team

Dr Deepankar Datta

Specialist Trainee Emergency Medicine

Julia Grahamslaw

Lead Research Nurse

Related news

Dip Dazzles at RCEM

Dip Dazzles at RCEM

9 Oct 2015 | Rachel O'Brien

Read more

More EMERGE Trials

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)